



EVENT BROCHURE

 **ANZ BIOLOGICS
FESTIVAL 2027**

Australia & New Zealand's Preeminent Biologics Conference

 24 - 25 February 2027 Melbourne, Australia

OFFICIAL EVENT BROCHURE

<https://infohub.imapac.com/anz-biologics-festival-2027>

Table of Contents

TESTIMONIALS	3
About the Event	4
Sponsors & Media Partners	5
2026 Speakers	6
Agenda At A Glance	7
Agenda	9
Expected Audience Snapshot	24
Who Should Sponsor?	25
Why Sponsor This Event?	25
Our Past Partners	26
Add to Calendar	27
Registration Form	28
About IMAPAC	29

EVENT CONTACTS

CONFERENCE PRODUCER

Caterin Sanggita

caterin.sanggita@imapac.com
+6569836137/+62811654788

Anusha Shirshyad

anusha.shirshyad@imapac.com
+6569645109

BUSINESS DEVELOPMENT MANAGER

George Gallagher

george.gallagher@imapac.com
+442046348767

EVENT HIGHLIGHTS

300+
ATTENDEES

120+
COMPANIES

50+
SPEAKERS

DATE & VENUE

24 - 25 February 2027

Melbourne
Australia

TESTIMONIALS

The ANZ Biologics Festival is always a great mix of academia and industry and provides a thoughtfully curated program of interesting talks across a diverse range of topics.

Senior Manager, Development, ACAMI
La Trobe University

If you are part of the biotech or supplier community developing novel therapeutics in Australia this event is definitely worth considering. Congratulations to the organisers. I hope and expect to see this event continue to grow and mature over time.

Non-Executive Director
FacioBiotherapies

Excellent conference to understand the Australian dynamic and Eco System on Biologic research and manufacturing.

Head of Global Clinical Manufacturing, mRNA CoE
Sanofi

The highlight of this event was the arrangement of the 1:1 meetings. Even if attendees showed interest during the presentations, there is always a chance they might not visit the booth afterward. By being able to pre-arrange meetings with targeted participants in advance, we were able to engage in much more efficient and focused networking.

Business Development Director
Pfanstiehl

It was a pleasure to attend and speak at the ANZ Biologic Festival, and I was impressed by the seamless organization and excellent arrangements. The event created a dynamic environment for networking and exchanging ideas with like-minded peers in the Australian Biopharma sector, offering outstanding networking opportunities. It was a truly rewarding and professionally valuable experience.

TheiaNova

About the Event

Excellence in Biologics Manufacturing, Cell and Gene Therapy, and RNA Therapeutics for Australia & New Zealand's Future Biologics Industry.

With a biotechnology sector benchmarked for global excellence due to world-class facilities, researchers, and regulation, the ANZ region has a promising future for biologics innovation and manufacturing. The path ahead will require a focus on further commercial translation of research, and as such, partnerships and collaborations will be critical. Expanding sovereign manufacturing in Australia & New Zealand will also play a massive role in uplifting the sector in the region.

The 5th annual ANZ Biologics Festival 2027 is the region's premier conference that aims to gather the innovators, pioneers, and leaders in the biologics fraternity, including Biologics, Biosimilars, Vaccines, Cell and Gene Therapy (CGT), and RNA Therapeutics, to showcase the latest from ideation to commercialization phase and beyond. It provides the right environment to meet the entire biopharma fraternity under one roof.

Join us to bring investment to Australia & New Zealand's bio sector and explore a wealth of opportunities in biologics innovation, expanding the region's manufacturing footprint, and advancing cell and gene therapy and RNA therapeutics. The 2027 festival will feature dedicated tracks on Biologics Manufacturing, Cell and Gene Therapy, and RNA Therapeutics, offering a comprehensive view of the latest advancements and challenges in these critical areas.

WHAT WE'LL COVER

Key Themes



R&D Innovation & Antibody Engineering

Explore the latest advances in biologics R&D, from monoclonal and bispecific antibodies to fusion proteins and next-generation therapies transforming biopharmaceutical innovation.



Manufacturing Excellence & Scalability

Learn how single-use systems, digital tools, and scalable processes are driving higher efficiency, flexibility, and quality across biologics manufacturing.



Clinical Trials & Regulatory Insights

Gain practical insights into early-phase clinical trials in ANZ, adaptive trial designs, faster regulatory pathways and alignment with global standards.



Supply Chain Optimisation

Discover strategies in cold chain logistics, smart packaging, and real-time temperature monitoring to strengthen biologics delivery networks.



Analytical & Quality Control Technologies

Explore the latest tools supporting biologics production, from GMP testing and automated quality control systems to advanced analytical technologies and comparability studies.



AI, Automation & Digital Transformation

See how AI, digital twins, and smart automation are reshaping biologics operations through predictive maintenance and process optimisation.

Sponsors & Media Partners

SILVER SPONSOR



EXHIBITORS



2026 SPEAKERS



Antiksha Joshi

Director of Quality
GPN Vaccines

AUSTRALIA



Dr. Peter Tobin

VP Head of Translational
Medicine

Telix Pharmaceutical
 AUSTRALIA



Dr. Jase Brouwer

CSO & Co-founder
Proxima Bio

AUSTRALIA



David Haylock

Chief Scientific Officer
VivaZome Therapeutics

AUSTRALIA



Kuldip Sidhu

Executive Director & Chief
Scientific Officer

CK Cell Technologies
 AUSTRALIA



Paul McDonald

Chief Executive Officer
RNA Australia

AUSTRALIA



Rakesh N. Veedu

Co-Founder & Managing
Director

ProGenis Pharmaceuticals
 AUSTRALIA



Rebecca Lim

Chief Scientific Officer
INOVIQ

AUSTRALIA



Shayanti Mukherjee

Head, Translational Tissue
Engineering Lab
Hudson Institute of Medical
Research

AUSTRALIA



Silvio Tiziani

Chief Executive Officer
Centre for Commercialisation of
Regenerative Medicine
Australia

AUSTRALIA



Dr. Con Panousis

Vice President, Drug Discovery
CSL

AUSTRALIA



Dr. Lauren Ely

Senior Director, Lead Discovery
and Protein Engineering
CSL

AUSTRALIA



Kathy Skoff

Head of Clinical Operations
Cartherics

AUSTRALIA



Dr. David Y. Fuller

Chief Medical Officer
Dimerix Limited

AUSTRALIA

Agenda At A Glance

CONFERENCE DAY 1 | 24TH FEBRUARY 2027, WEDNESDAY

ANZ Biologics & Next-Gen Therapeutics Forum

CGT FORUM

Leadership Panel Discussion

Australia's Role in Shaping the Future of the Global Advanced Therapeutics Landscape

MORNING TEA, EXHIBITION VIEWING, POSTER PRESENTATIONS & 1-1 ATTENDEE NETWORKING

Clinical Trials Innovation & Translational Medicine

Clinical Translation of Cell & Gene Therapies

From Preclinical Development to First-in-Human Studies

LUNCH, EXHIBITION VIEWING, POSTER PRESENTATIONS & 1-1 ATTENDEE NETWORKING

Advanced Bioprocessing & Manufacturing for Next-Gen Therapeutics

CGT Manufacturing & CMC Development

Scale-Up, Tech Transfer & Commercial Readiness

AFTERNOON TEA, EXHIBITION VIEWING, POSTER PRESENTATIONS & 1-1 ATTENDEE NETWORKING

ADCs, Bispecific Antibodies & Emerging Biologic Modalities

Next-Generation Cell & Gene Therapies

Advancing CAR-T, NK Cell Platforms, Gene Editing and Advanced Delivery Technologies

END OF CONFERENCE DAY 1

AWARDS 2027

Agenda At A Glance

CONFERENCE DAY 2 | 25TH FEBRUARY 2027, THURSDAY

ANZ Biologics & Next-Gen Therapeutics Forum	RNA FORUM
GMP Manufacturing, Quality Control & Regulatory Readiness	Scalable RNA Manufacturing Process Development, Platform Technologies & Production Strategies
MORNING TEA, EXHIBITION VIEWING, POSTER PRESENTATIONS & 1-1 ATTENDEE NETWORKING	
AI, Digitalization & Data-Driven Biologics Development	RNA Delivery Technologies & Targeted Delivery Systems
LUNCH, EXHIBITION VIEWING, POSTER PRESENTATIONS & 1-1 ATTENDEE NETWORKING	
ANZ Emerging Biopharma Showcase	Next-Generation RNA Therapeutics Oligonucleotides, Circular RNA & Precision Medicines
AFTERNOON TEA, EXHIBITION VIEWING, POSTER PRESENTATIONS & 1-1 ATTENDEE NETWORKING	
Supply-Chain Management & Temperature Controlled Logistics	Regulatory Pathways, Clinical Translation & Commercialisation of RNA Therapeutics
END OF CONFERENCE	

Day 1

Wednesday, 24 February 2027

ANZ Biologics & Next-Gen Therapeutics Forum

CGT FORUM

8:50

IMAPAC Opening Address

8:55

Chairman's Welcome Address

Leadership Panel Discussion: Australia's Role in Shaping the Future of the Global Advanced Therapeutics Landscape

9:00

Leadership Panel Discussion: Australia's Role in Shaping the Future of the Global Advanced Therapeutics Landscape

- How can Australia strengthen its position as a global hub for advanced therapeutics innovation, clinical translation, and manufacturing?
- What ecosystem capabilities are needed to accelerate cell and gene therapy development, commercialisation, and patient access?
- How can industry, academia, government, and investors collaborate to build a sustainable advanced therapeutics ecosystem?

9:45

Enabling the Future of Advanced Therapies: Innovative Technologies for Scalable Cell & Gene Therapy Manufacturing

- Advancing next-generation manufacturing platforms to improve scalability, consistency, and cost efficiency
- Supporting automation, digitalisation, and closed-system solutions for advanced therapy production
- Addressing key challenges in process development, quality control, and commercial-scale manufacturing



Reserved for Solution Provider

ANZ Biologics & Next-Gen Therapeutics Forum

CGT FORUM

10:00

Building Australia's Cell and Gene Therapy Commercialisation Ecosystem: Connecting Research, Manufacturing, Investment and Patient Access

- The current state of Australia's cell and gene therapy ecosystem and opportunities for future growth
- Addressing the commercialisation gap through coordinated investment, infrastructure development and industry partnerships
- Building globally connected pathways to accelerate translation, manufacturing scale-up and patient access

**Silvio Tiziani**

Chief Executive Officer, Centre for Commercialisation of Regenerative Medicine Australia

10:25

Morning Tea, Exhibition Viewing & 1-1 Attendee Networking**Clinical Trials Innovation & Translational Medicine****Clinical Translation of Cell & Gene Therapies: From Preclinical Development to First-in-Human Studies**

11:10

Positioning Australia & New Zealand as a Global Hub for Early-Phase Clinical Trials

- Competitive advantages of the ANZ clinical trial ecosystem
- Regulatory pathways enabling faster trial initiation
- Attracting international investment and partnerships
- Building globally competitive translational research capabilities

11:10

Accelerating Cell Therapy Innovation: Advancing Stem Cell and Regenerative Medicine Towards Clinical Translation *(TBC)***Kuldip Sidhu**

Executive Director & Chief Scientific Officer, CK Cell Technologies

ANZ Biologics & Next-Gen Therapeutics Forum

11:35

Maximising Clinical Success: Strategies to Reduce Risk, Cost & Time to Market

- Improving clinical trial productivity
- Innovative partnership models between biotech, CROs and academia
- Balancing speed with quality and compliance
- Preparing biologics for successful commercialisation

**Reserved for Solution Provider**

11:50

Accelerating Translation: Bridging Discovery to Commercial Success in Biologics

- Closing the gap between laboratory discovery and first-in-human studies
- Strategies to de-risk biologics development and improve clinical success rates
- Strengthening industry-academia collaboration for faster translation
- Building sustainable commercial pathways for innovative therapeutics

11:35

Enabling Clinical Translation: Advanced Platforms and Technologies for Accelerating Cell & Gene Therapy Development

- Supporting seamless transition from research-grade to clinical-grade manufacturing through innovative solutions
- Improving process optimisation, analytical capabilities, and quality control for advanced therapies
- Leveraging automation and digital technologies to enhance reproducibility and scalability

**Reserved for Solution Provider**

11:50

Preparing for First-in-Human Clinical Trials: Translating CTH-401 CAR-T Therapy from Development to Ovarian Cancer Patients (TBC)**Kathy Skoff**

Head of Clinical Operations, Cartherics

12:15

Lunch, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking**Advanced Bioprocessing & Manufacturing for Next-Gen Therapeutics****CGT Manufacturing & CMC Development: Scale-Up, Tech Transfer & Commercial Readiness**

ANZ Biologics & Next-Gen Therapeutics Forum

1:30

Manufacturing Complex Biologics: Overcoming Process Development & Scale-Up Challenges

- Manufacturing monoclonal antibodies, ADCs and fusion proteins
- Process robustness and product consistency
- Improving yield, productivity and quality attributes
- Technology innovations supporting complex biologics

1:55

Manufacturing Innovation for Complex Biologics: Driving Productivity, Quality & Speed

- Advanced manufacturing platforms for complex biologics
- Process intensification and continuous bioprocessing
- Improving product quality and manufacturing consistency
- Reducing development timelines through innovation



Reserved for Solution Provider

CGT FORUM

1:30

CGT Manufacturing & CMC Development: Scale-Up, Tech Transfer & Commercial Readiness

- Building robust CMC strategies to support the transition from early development to commercial manufacturing
- Managing scale-up challenges, technology transfer, and process consistency across manufacturing sites
- Preparing cell and gene therapies for regulatory approval and commercial launch

1:55

Accelerating CGT Manufacturing Success: Advanced Technologies for Scalable and Flexible Production

- Enabling scalable manufacturing through innovative platforms, automation, and process optimisation
- Supporting efficient technology transfer and global manufacturing alignment
- Improving quality, cost efficiency, and operational flexibility for commercial-scale CGT production



Reserved for Solution Provider

ANZ Biologics & Next-Gen Therapeutics Forum

2:10

Accelerating CMC Development for Next-Generation Therapeutics

- Integrating CMC early in product development
- Analytical strategies for complex biologics
- Manufacturing readiness for regulatory submissions
- Accelerating timelines without compromising quality

2:35

Smart Bioprocessing: Leveraging AI, Automation & Digital Twins for Manufacturing Excellence

- AI-driven process monitoring and optimisation
- Digital twins for predictive manufacturing
- Advanced analytics and real-time quality control
- Data-driven decision making across manufacturing operations

3:00

Afternoon Tea, Exhibition Viewing & 1-1 Attendee Networking

ADCs, Bispecific Antibodies & Emerging Biologic Modalities

CGT FORUM

2:10

Building Commercial-Ready Cell & Gene Therapy Manufacturing Ecosystems

- Developing sustainable manufacturing models to meet growing demand for advanced therapies
- Strengthening partnerships across biotech, CDMOs, and technology providers to accelerate market readiness
- Addressing regulatory, supply chain, and operational considerations for long-term commercial success

2:35

From Clinical Success to Commercial Reality: Scaling Cell & Gene Therapies for Global Patient Access

- Lessons learned from transitioning advanced therapies into commercial manufacturing
- Balancing speed, quality, cost, and regulatory expectations during scale-up
- Creating resilient ecosystems to support global distribution and patient access

Next-Generation Cell & Gene Therapies: Advancing CAR-T, NK Cell Platforms, Gene Editing and Advanced Delivery Technologies

ANZ Biologics & Next-Gen Therapeutics Forum

3:40

Cell-Surface Degraders: Reprogramming Protein Turnover for Autoimmune Disease

- Harnessing cell-surface E3 ligases to selectively degrade disease-driving immune receptors
- Achieving deeper, more durable and cell-selective target suppression beyond conventional antibody blockade
- Expanding the druggable target space and therapeutic window for challenging cell-surface targets

**Dr. Jase Brouwer**

CSO & Co-founder, Proxima Bio

4:05

Manufacturing Complex Biologics: Scaling ADCs & Bispecific Antibodies for Global Markets

- Process development and analytical strategies
- Manufacturing highly potent biologics
- Quality control and regulatory expectations
- Scaling production while maintaining consistency

CGT FORUM

3:40

Extracellular Vesicle Therapeutics: Emerging Cell-Free Platforms for Next-Generation Medicine (TBC)**David Haylock**

Chief Scientific Officer, VivaZome Therapeutics

4:05

Enabling Next-Generation Cell & Gene Therapies: Innovations in Gene Editing, Delivery Systems and Manufacturing Platforms

- Supporting advanced therapy development through innovative vector technologies, delivery platforms, and manufacturing solutions
- Improving scalability, process control, and quality attributes for emerging cell and gene therapy modalities
- Accelerating translation from research breakthroughs to clinical and commercial applications

**Reserved for Solution Provider**

ANZ Biologics & Next-Gen Therapeutics Forum

4:20

Panel Discussion: The Next Wave of Targeted Biologic Innovation – Advancing ADCs, Bispecific Antibodies & Emerging Therapeutic Modalities

- Which next-generation biologic modalities are poised to transform the future of precision medicine?
- Advancing ADCs, bispecific antibodies, multispecifics, radiopharmaceuticals and other emerging biologics from discovery to clinical success.
- Overcoming development, manufacturing and regulatory challenges to accelerate commercialisation.
- Strengthening collaboration across biotech, pharma, academia and investors to drive the next generation of biologic innovation.

CGT FORUM

4:20

Next-Generation Cell Therapies: Translational Tissue Engineering Approaches for Advanced Therapeutic Applications (TBC)**Shayanti Mukherjee**Head, Translational Tissue Engineering Lab,
Hudson Institute of Medical Research

4:45

Shaping the Future of Advanced Therapies: From Scientific Breakthroughs to Real-World Impact

- Identifying the next wave of innovations transforming the advanced therapeutics landscape
- Balancing innovation, affordability, and accessibility in future therapy development
- Strengthening partnerships across industry, academia, and healthcare systems

5:15

END OF CONFERENCE DAY 1

5:10

END OF CONFERENCE DAY 1

6:00

AWARDS 2027

Day 2

Thursday, 25 February 2027

ANZ Biologics & Next-Gen Therapeutics Forum

8:50

IMAPAC Opening Address

8:55

Chairman's Welcome Address

GMP Manufacturing, Quality Control & Regulatory Readiness

9:00

Quality by Design for Advanced Therapeutics: Strengthening GMP and Quality Systems for Commercial Readiness (TBC)



Antiksha Joshi

Director of Quality, GPN Vaccines

RNA FORUM

8:50

IMAPAC Opening Address

8:55

Chairman's Welcome Address

Scalable RNA Manufacturing: Process Development, Platform Technologies & Production Strategies

9:00

Panel Discussion: Scaling RNA Manufacturing: Building the Future of RNA Therapeutics Production

- How can the industry overcome key challenges in scaling RNA manufacturing from clinical development to commercial production?
- What capabilities, technologies, and partnerships are needed to build resilient RNA manufacturing ecosystems?
- How can companies balance innovation, cost efficiency, quality requirements, and regulatory expectations in RNA production?

ANZ Biologics & Next-Gen Therapeutics Forum

9:25

Next-Generation Quality Control: Leveraging Advanced Analytics for Faster Product Release

- Rapid microbiological methods and real-time testing
- PAT and advanced analytical technologies
- AI-enabled quality control and release testing
- Reducing release timelines while ensuring compliance



Reserved for Solution Provider

9:45

Panel Discussion: Future-Ready GMP Strengthening Manufacturing, Quality & Regulatory Excellence for Next-Generation Therapeutics

- How are GMP expectations evolving for biologics, RNA therapeutics, and advanced therapies?
- Balancing innovation, speed, and regulatory compliance.
- Digital transformation and AI in quality management systems.
- Building resilient manufacturing operations for global commercialisation.

9:45

Enabling Scalable RNA Production: Innovative Platforms for Efficient Manufacturing and Process Optimisation

- Leveraging advanced technologies to improve RNA production efficiency, yield, and reproducibility
- Supporting flexible manufacturing approaches through automation, modular platforms, and process optimisation
- Enhancing analytical capabilities and quality control strategies for next-generation RNA products



Reserved for Solution Provider

10:00

Advancing RNA Therapeutics from Development to Commercial Manufacturing: Real-World Strategies and Challenges

- Navigating process development, technology transfer, and scale-up challenges for RNA-based therapies
- Strengthening manufacturing readiness and supply chain strategies for clinical and commercial success
- Building collaborations across biotech, CDMOs, and technology providers to accelerate RNA therapeutic innovation

10:25

Morning Tea, Exhibition Viewing & 1-1 Attendee Networking

ANZ Biologics & Next-Gen Therapeutics Forum

RNA FORUM

AI, Digitalization & Data-Driven
Biologics Development

11:10

Harnessing AI, Bioinformatics & Digital Technologies to Accelerate Next-Generation Biologics Development

- AI and computational biology accelerating biologics discovery and optimisation
- Bioinformatics and multi-omics enabling precision therapeutic development
- Digital transformation across CMC, manufacturing and quality operations
- Building integrated, data-driven biologics development ecosystems

11:10

RNA Delivery Technologies & Targeted Delivery Systems: Advancing Precision Therapeutics

- Exploring emerging delivery platforms including lipid nanoparticles, viral and non-viral systems for RNA therapeutics
- Improving targeting, stability, safety, and efficacy of RNA delivery approaches
- Translating innovative delivery technologies into clinically viable RNA-based therapies

ANZ Biologics & Next-Gen Therapeutics Forum

11:35

From Data to Discovery: AI, Bioinformatics & Computational Biology in Next-Generation Therapeutics

- Leveraging AI, genomics, proteomics and bioinformatics to accelerate biologics and therapeutic discovery.
- Harnessing computational biology and multi-omics to advance biomarker discovery, precision medicine and translational research.
- Integrating AI-driven analytics and digital technologies to improve clinical decision-making and drug development.
- Building data-driven strategies that accelerate innovation, optimise R&D, and support successful clinical and commercial outcomes.



Reserved for Solution Provider

11:50

From Algorithms to Impact: Scaling AI Across the Biologics Value Chain

- Embedding AI across R&D, CMC, manufacturing and regulatory functions
- Building connected digital ecosystems for end-to-end biologics development
- Overcoming data integration, governance and interoperability challenges
- Measuring business value and accelerating organisational adoption

RNA FORUM

11:35

Next-Generation RNA Delivery Platforms: Enabling Efficient and Targeted Therapeutic Delivery

- Advancing delivery technologies to improve biodistribution, cellular uptake, and therapeutic performance.
- Developing scalable and robust delivery platforms for diverse RNA modalities.
- Supporting faster development timelines through innovative formulation and analytical solutions



Reserved for Solution Provider

11:50

Overcoming RNA Delivery Challenges: From Research Innovation to Clinical Translation

- Addressing key barriers in RNA delivery including immunogenicity, targeting precision, and manufacturing complexity
- Optimising delivery strategies for different therapeutic applications and patient populations
- Building partnerships to accelerate RNA therapeutics from discovery to clinical success

12:15

Lunch, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking

ANZ Biologics & Next-Gen Therapeutics Forum

RNA FORUM

ANZ Emerging Biopharma Showcase

Next-Generation RNA Therapeutics: Oligonucleotides, Circular RNA & Precision Medicines

1:30

Innovators to Watch: Showcasing Australia's & New Zealand's Next Generation of Biopharma Leaders

- Breakthrough biologics and therapeutic innovations from emerging biopharma
- Translating cutting-edge science into clinical and commercial success
- Emerging technologies addressing unmet medical needs
- Building partnerships to accelerate global growth

1:30

Chemistry, Design, and Dynamics of Splice-Switching Antisense Oligonucleotide Therapeutics *(TBC)*

- How antisense oligonucleotides (ASOs) efficiently target pre-messenger RNA to modulate splicing and regulate gene expression
- Clinical progress and lessons learned from approved splice-switching ASO therapies for Duchenne muscular dystrophy and spinal muscular atrophy
- Current nucleotide and backbone linkage chemistries shaping the ASO therapeutic landscape
- Advancing next-generation splice-switching ASOs through novel chemistries, improved designs, and enhanced therapeutic performance

**Rakesh N. Veedu**

Co-Founder & Managing Director, ProGenis Pharmaceuticals

ANZ Biologics & Next-Gen Therapeutics Forum

1:55

Emerging Biopharma Spotlight: Accelerating Innovation from Discovery to Commercialisation

- Translational science driving next-generation therapeutics
- Overcoming funding and development challenges
- Building scalable and investment-ready companies
- Partnering with global biopharma for market expansion

**Reserved for Solution Provider**

2:10

Panel Discussion: Scaling ANZ Biopharma Innovation from Startup to Global Success

- What does it take to build a globally competitive biotech?
- Accessing capital, partnerships and manufacturing capabilities
- Navigating clinical development and regulatory pathways
- Positioning ANZ innovation on the global stage

RNA FORUM

1:55

Enabling Next-Generation RNA Therapeutics: Advanced Technologies for Development, Manufacturing and Delivery

- Supporting RNA therapeutic development through innovative platforms, analytical tools, and manufacturing solutions
- Improving scalability, quality control, and production efficiency for emerging RNA modalities
- Accelerating translation of RNA innovations through integrated technology solutions and partnerships

**Reserved for Solution Provider**

2:10

Australia's RNA Therapeutics Ecosystem: Building Capability, Collaboration and Innovation Across the RNA Landscape (TBC)**Paul McDonald**

Chief Executive Officer, RNA Australia

ANZ Biologics & Next-Gen Therapeutics Forum

RNA FORUM

2:35

The Future of RNA Medicine: Transforming Breakthrough Science into Real-World Therapeutic Solutions

- Identifying the next wave of RNA innovations shaping the future of healthcare
- Balancing scientific advancement with manufacturing, regulatory, and commercial considerations
- Strengthening collaborations across biotech, academia, and industry to accelerate RNA medicine adoption

3:00

Afternoon Tea, Exhibition Viewing & 1-1 Attendee Networking

Supply-Chain Management & Temperature Controlled Logistics**Regulatory Pathways, Clinical Translation & Commercialisation of RNA Therapeutics**

3:40

Delivering Complex Biologics: Overcoming Supply Chain & Temperature-Controlled Logistics Challenges

- Logistics strategies for ADCs and advanced biologics
- Managing ultra-low temperature storage and transportation
- Ensuring product integrity across global supply networks
- Risk mitigation and contingency planning

3:40

Regulatory Pathways, Clinical Translation & Commercialisation of RNA Therapeutics

- Navigating evolving regulatory frameworks for RNA therapeutics and accelerating pathways from clinical development to approval
- Addressing key challenges in clinical translation, manufacturing readiness, and long-term safety monitoring
- Building sustainable strategies for commercialisation, market access, and global adoption of RNA medicines

ANZ Biologics & Next-Gen Therapeutics Forum

4:05

Future-Proofing Biologics Supply Chains: From Cold Chain Excellence to Digital Logistics

- Next-generation cold chain technologies for biologics
- AI-enabled forecasting and inventory optimisation
- Building resilient global distribution networks
- Sustainability and carbon reduction across the supply chain

4:30

Smart Supply Chains for Next-Generation Therapeutics

- AI and predictive analytics transforming supply chain operations
- Real-time monitoring through IoT and smart packaging
- Digital supply chain visibility and traceability
- Building agile supply networks for future therapeutics

4:55

Chairman's Closing Remarks

5:00

END OF CONFERENCE

RNA FORUM

4:05

Accelerating RNA Therapeutics Development: Regulatory, Analytical and Manufacturing Solutions for Clinical Success

- Supporting regulatory submissions through advanced analytical platforms, quality strategies, and development solutions
- Enabling efficient clinical translation through improved process characterisation and manufacturing readiness
- Helping organisations overcome regulatory and operational barriers from early development to commercial launch

4:30

From Clinical Breakthroughs to Market Access: Real-World Strategies for Commercialising RNA Therapeutics

- Translating promising RNA technologies into clinically validated and commercially viable therapies
- Optimising clinical development strategies, regulatory engagement, and market access planning
- Establishing partnerships and business models to accelerate patient access to RNA medicines

4:55

Chairman's Closing Remarks

5:00



END OF CONFERENCE

Expected Audience Snapshot





87%BIOPHARMA, BIG PHARMA, CMOS/CDMOS &
CROS ACROSS ANZ**80%**

DECISION MAKERS

BY PROFILE

Big Pharma **37%**Australia Biopharma **26%**CMOs & CDMOs **15%**CROs **9%**Technology & Service
Providers **9%**Investors, Government,
Others **4%**

BY JOB TITLE

C-Level Executives **12%**VPs, Directors, Heads of
Process Development,
Manufacturing &
Bioprocessing/MSAT **33%**VPs, Directors, Heads of
Clinical Trials &
Development & R&D **19%**Head of Quality
Assurance, Control and
Analytics **13%**Supply Chain & Logistics
Leaders **10%**Business Development &
Marketing Professionals **13%**

BY GEOGRAPHY

22%APAC (excl.
ANZ)**11%**Rest of The
World**11%**Perth/Western
Australia**11%**Rest of
Australia**23%**

New Zealand

22%Sydney/Melbou
rne

Who Should Sponsor?

BIOMANUFACTURING SOFTWARE

CELL CULTURE AND FERMENTATION

PROCESS OPTIMIZATION

CRYOPRESERVATION

HIGH-THROUGHPUT SCREENING

MICROFLUIDICS

BIOSENSOR TECHNOLOGY

GENE THERAPY TECHNOLOGY

SINGLE-USE TOOLS

DRUG DELIVERY

BIOPROCESSING EQUIPMENT

CELL LINE DEVELOPMENT

NEXT-GENERATION SEQUENCING

BIOINFORMATICS

BIOSENSOR TECHNOLOGY

AUTOMATION AND ROBOTICS

3D BIOPRINTING

GENE EDITING

CONTINUOUS MANUFACTURING

Why Sponsor This Event?

Thought Leadership

Present Your Expertise to the Biopharma Industry's Key Stakeholders through a Variety of Available Speaking Packages.

Host a Panel Discussion

Moderate a panel discussion including one representative from your company with 3 representatives from the end user side to share views on a current industry topic

Duration: 45 minutes

Showcase Your Solutions to Educate the Market

Join in for dedicated CMO & CRO Showcases for German Market

Branding

Emphasize on your Message by Marketing and Promoting Alongside the Event

Networking & Lead Generation

Gain Exclusive Access to Contacts of High Profile Attendees through Intimate Networking Opportunities

Our Past Partners



MARK YOUR CALENDAR

Save the Date

24–25 FEB
2027

 Melbourne

ANZ Biologics Festival 2027

ALL IMAPAC EVENTS



Explore Our Full Event Calendar

Discover all upcoming and future IMAPAC events across Asia-Pacific — biopharmaceutical conferences, summits, and exhibitions for the year ahead.



OR ADD THIS EVENT TO YOUR CALENDAR



Google Calendar

One-click add to Gmail



Outlook Calendar

Add to Microsoft Outlook



Scan to Register

Open camera, point at code, instant registration access.

Or click the QR to open registration directly.

CATEGORY	EARLY BIRD (By 5 Sep 2026)	REGISTRATION (By 7 Nov 2026)	STANDARD (By 9 Jan 2027)	FINAL CALL
BIOPHARMA, ACADEMIC & RESEARCH — BASED IN ASIA (APAC)				
2-Day Conference Pass Job Profiles: Manufacturing, Bioprocessing, Production, USP, DSP, Operations, Site Heads, Drug Substance and Product Manufacturing, Process Development, Quality, Analytics and other related technical designations	SGD 1,495	SGD 1,695	SGD 1,895	SGD 2,095
BIOPHARMA, ACADEMIC & RESEARCH — BASED OUTSIDE OF ASIA				
2-Day Conference Pass Job Profiles: Manufacturing, Bioprocessing, Production, USP, DSP, Operations, Site Heads, Drug Substance and Product Manufacturing, Process Development, Quality, Analytics and other related technical designations	SGD 1,995	SGD 2,195	SGD 2,395	SGD 2,595
BIG PHARMA, SOLUTION / SERVICE / TECHNOLOGY PROVIDERS & CDMO/CMO				
2-Day Conference Pass Business Development, Marketing & Sales profiles	SGD 2,995	SGD 3,195	SGD 3,395	SGD 3,595
BRING YOUR TEAM - Group Discount				
Asia & International Biopharma - Buy 2, Get 3 passes - Buy 3, Get 5 passes Limited to professionals in the "BUYER" profile working in Process Development, R&D, QC & Assurance, Manufacturing Heads, Engineering, Upstream, Downstream or Analytical in Big Pharmas, International / Asian Biopharmas, and Academic & Research Institutes. INNER CIRCLE Speaker referrals and professionals working in the same organisation as our speakers are entitled to a 15% discount. - Access to all conference proceedings for up to 30 days. - Site Tour Package is applicable only with the purchase of a conference pass. Standard Package Group Discount 3 Delegates Save 10% 5 Delegates Save 20% 6+ Delegates Save 25%				

EVENT VENUE



Melbourne, Australia
24 - 25 February 2027

3 EASY WAYS TO REGISTER

Online
Visit:
<https://www.imapac.com/events/anz-biologics-festival-2027#register>

Telephone
+65 6983 6140 (SG) / +44 161 552 8507 (UK)

Mail
Cheque payable to IMAPAC Pte Ltd,
36 Robinson Road, #02-01
068877
Singapore

Cheque payable to IMAPAC UK Ltd,
77 Farringdon Road, Farringdon, London
EC1M 3JU
United Kingdom

YOUR DETAILS

Name

Job Title

Address

Postcode

Tel

Email

Your primary business

Authorising Manager

Organization

Country

Fax

Authorising manager signature

PAYMENT DETAILS

Payment is due immediately upon receipt of this registration form if you pay by credit card or 3 working days after your receipt of payment notification. Non-credit card payment will incur an additional US\$100 (Bank handling fee)

I want to pay: ☐ Credit Card ☐ Bank Transfer ☐ Cheque

Offline credit card: ☐ Visa ☐ MasterCard ☐ American Express

Online credit card payment: Please register at <https://www.imapac.com/events/anz-biologics-festival-2027#register>

Name on Card

Expiry Date (MM/YY)

Card Number

CVC Code

Signature

TERMS & CONDITIONS

Payment & Registration
Full payment is due upon registration if you pay by credit card, or 3 working days after receipt of invoice. Registration will not be confirmed until full payment has been received. Unpaid registration will be billed 50% of the registration fee if you do not attend the event. A copy of the conference documentation will be mailed to you. Staff at the event will request a credit card guarantee for delegates without proof of payment.

Ticket Classification
All registrations are reviewed to ensure correct classification. Biopharma tickets are reserved for professionals employed by pharmaceutical or biopharmaceutical companies that develop, own or commercialise therapeutic drug products. Service, Solution and Technology Provider tickets apply to organisations offering services, platforms, technologies, equipment, consultancy or manufacturing services to the industry (including CROs, CDMOs, vendors, consultants and suppliers). Purchasing an incorrect ticket does not guarantee entry. IMAPAC retains full discretion to deny access, reclassify registrations and issue an invoice for the price difference. Incorrect ticket purchases under an inappropriate classification are not eligible for refunds under any circumstances.

Cancellation & Substitution Policy
Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference, attendees will receive a full credit note towards a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organisation can be made at any time in writing at no extra charge. In the event that IMAPAC cancels a conference, payments received at the cancellation date will be credited towards attendance at a future conference, or in the event of postponement by IMAPAC, towards the rescheduled date. Credit notes remain valid for twelve months.

Changes to Conference & Agenda
IMAPAC reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers for an event. IMAPAC is not responsible for any loss or damage as a result of substitution, alteration, postponement or cancellation of an event due to causes beyond its control including, without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities. In the event that a conference is cancelled, IMAPAC is not liable for any costs incurred by delegates in connection with their attendance. Changes to the agenda will be updated on our website as soon as possible.

Data Protection
The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to reputable third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: data@imapac.com.

A VARIETY OF PRODUCTS TO CATER TO GLOBAL BIOPHARMACEUTICAL INDUSTRY'S MARKET INTELLIGENCE AND BUSINESS CONNECTIONS NEEDS.

01 B2B EVENTS

Thought-leadership, industry knowledge-sharing and quality networking are at the core of IMAPAC's B2B events.

Create an engaging experience for your audiences, explore our B2B Events Solutions.

02 360 MARKETING SOLUTIONS

Expand your reach and influence! Be it with customized events, digital marketing solutions, content creation or thought-leadership.

Tap into our pool of audience that spans across various sub-sectors and regions critical in the burgeoning APAC biopharmaceutical sector.

03 DASHBOARDS

A quick-view analytics tool to power your decisions. Access region or country-specific data to uncover pipeline information, product focus.

Customize the dashboard based on your needs. Drill down to the data you need using custom views.

04 CUSTOM RESEARCH

Based on your objectives and budget, you can customize a package to one that best meets your intelligence needs. This allows you to maximize your ROI without spending on items that are not in line with your strategies.

With access to a database of 60,000+ life science professionals. We conduct research with a highly-qualified audience.

05 REPORTS

Discover in-depth market information of the growing biopharmaceutical sector.

[Learn More →](#)



HELPING THE GLOBAL BIOPHARMACEUTICAL INDUSTRY

Generate Tangible Growth

IMAPAC is the one-stop shop of market intelligence and business connections for the global biopharmaceutical industry. We help companies expand their influence, make data driven decisions through our industry intelligence, and link up with other biopharmaceutical professionals to exchange knowledge and engage in quality networking. At the

core of IMAPAC is our mission to help biopharmaceutical businesses globally generate tangible growth. At the same time, our heart lies in giving back to society. We empower the next generation by equipping underprivileged children with an education.

WEBSITE

imapac.com

EMAIL

info@imapac.com

IMAPAC PTE LTD

36 Robinson Road, #02-01
Singapore 068877
+65 6983 6140

IMAPAC UK LTD

77 Farringdon Road, Farringdon
London EC1M 3JU, United Kingdom
+44 161 552 8507

CONNECT WITH US

LINKEDIN

@imapac

X

@imapac

FACEBOOK

ImapacPteLtd